Skip to content
FindTrial
Search trials
Search trials by condition, treatment, sponsor...
Sign In
Onapristone ER
DRUG
2 trials
Sponsors
Memorial Sloan Kettering Cancer Center
Conditions
Endometrioid Endometrial Cancer
Granulosa Cell Ovarian Cancer
Low Grade Serous Ovarian/ Primary Peritoneal Cancer
Metastatic Breast Cancer
Unresectable Breast Cancer
Phase 1
A Study of Letrozole, Palbociclib, and Onapristone ER in People With Metastatic Breast Cancer
Withdrawn
NCT04872608
Memorial Sloan Kettering Cancer Center
Metastatic Breast Cancer, Unresectable Breast Cancer
Start: 2021-09-09
End: 2023-04-25
Updated: 2023-04-28
Phase 2
A Study of Onapristone ER Alone Or In Combination With Anastrozole in Gynecologic Cancers That Respond to Progesterone
Completed
NCT03909152
Memorial Sloan Kettering Cancer Center
Endometrioid Endometrial Cancer, Granulosa Cell Ovarian Cancer, Low Grade Serous Ovarian/ Primary Peritoneal Cancer
Start: 2019-05-02
End: 2024-09-03
Updated: 2025-07-28
Related Papers
Basket study of oral progesterone antagonist onapristone extended release (ONA-XR) in progesterone receptor positive (PR+) recurrent granulosa cell (GCT), low-grade serous ovarian (LGSOC), or endometrioid endometrial cancer (EEC).
Journal of Clinical Oncology
2022-06-01
2 citations
Basket study of the oral progesterone antagonist onapristone ER in women with progesterone receptor positive (PR+) recurrent granulosa cell tumor (GCT), low-grade serous ovarian cancer (LGSOC), or endometrioid endometrial cancer (EEC).
Journal of Clinical Oncology
2020-05-20
2 citations
Targeting Progesterone in Hormonally Responsive Ovarian Cancer
Oncology Times
2019-11-26